Albumin orchestrates a natural host defense mechanism against mucormycosis
2024

Albumin's Role in Fighting Mucormycosis

Sample size: 97 publication 10 minutes Evidence: high

Author Information

Author(s): Pikoulas Antonis, Morianos Ioannis, Nidris Vassilis, Hamdy Rania, López-López Angeles, Moran-Garrido Maria, Muthu Valliappan, Halabalaki Maria, Papadovasilaki Maria, Irene Kyrmizi, Gu Yiyou, Aerts Robina, Mercier Toine, Vanbiervliet Yuri, Cho Sung-Yeon, Spallone Amy, Samonakis Dimitrios, Kastritis Efstathios, Drakos Elias, Tzardi Maria, Eliopoulos Aristides, Georgila Konstantina, Carvalho Agostinho, Kurzai Oliver, Rudramurthy Shivaprakash, Lanternier Fanny, Maertens Johan, Bruno Vincent, Kontoyiannis Dimitrios, Barbas Coral, Soliman Sameh, Ibrahim Ashraf, Chamilos Georgios

Primary Institution: University of Crete

Hypothesis

Albumin plays a master regulatory role in host defense against Mucorales by modulating fungal pathogenicity.

Conclusion

The study reveals that albumin inhibits the growth of Mucorales and prevents the expression of virulence factors, suggesting its potential as a therapeutic target in mucormycosis.

Supporting Evidence

  • Severe hypoalbuminemia is a common finding in patients with mucormycosis.
  • Albumin inhibits Mucorales growth among a range of human pathogens.
  • Albumin-bound free fatty acids block the expression of the mycotoxin mucoricin.
  • Albumin-deficient mice display susceptibility specifically to mucormycosis.
  • Patients with very low albumin levels had significantly lower survival rates.

Takeaway

Albumin helps our body fight off a dangerous fungus called Mucorales by stopping it from growing and causing harm.

Methodology

The study involved analyzing serum samples from patients, conducting in vitro assays with albumin, and using mouse models to assess the antifungal activity of albumin.

Potential Biases

Potential biases may arise from the selection of patient cohorts and the specific conditions under which the experiments were conducted.

Limitations

The study primarily focuses on specific patient cohorts and may not generalize to all populations.

Participant Demographics

Patients with hematological malignancies and metabolic disorders, including diabetes and COVID-19.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.21203/rs.3.rs-5441197

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication